127 related articles for article (PubMed ID: 21928377)
1. Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.
Wang C; Lu J; Wang Y; Bai S; Wang Y; Wang L; Sheng G
J Biochem Mol Toxicol; 2012 Jan; 26(1):35-43. PubMed ID: 21928377
[TBL] [Abstract][Full Text] [Related]
2. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
3. Effect of small interfering RNA targeting wild-type FLT3 in acute myeloid leukaemia cells in vitro and in vivo.
Wang CM; Sheng GY; Lu J; Xie L; Bai ST; Xu XJ; Liu YF
J Int Med Res; 2011; 39(5):1661-74. PubMed ID: 22117966
[TBL] [Abstract][Full Text] [Related]
4. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.
Griessinger E; Imbert V; Lagadec P; Gonthier N; Dubreuil P; Romanelli A; Dreano M; Peyron JF
Leukemia; 2007 May; 21(5):877-85. PubMed ID: 17330097
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
[TBL] [Abstract][Full Text] [Related]
6. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
Kasper S; Breitenbuecher F; Hoehn Y; Heidel F; Lipka DB; Markova B; Huber C; Kindler T; Fischer T
Leuk Res; 2008 Nov; 32(11):1698-708. PubMed ID: 18556063
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
[TBL] [Abstract][Full Text] [Related]
9. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM
Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086
[TBL] [Abstract][Full Text] [Related]
10. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
12. Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
Griessinger E; Frelin C; Cuburu N; Imbert V; Dageville C; Hummelsberger M; Sirvent N; Dreano M; Peyron JF
Leukemia; 2008 Jul; 22(7):1466-9. PubMed ID: 18239622
[No Abstract] [Full Text] [Related]
13. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
Heidary DK; Huang G; Boucher D; Ma J; Forster C; Grey R; Xu J; Arnost M; Choquette D; Chen G; Zhou JH; Yao YM; Ball ED; Namchuk M; Davies RJ; Henkel G
J Med Chem; 2012 Jan; 55(2):725-34. PubMed ID: 22221201
[TBL] [Abstract][Full Text] [Related]
14. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
16. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.
Nishiyama U; Yoshino T; Ozai M; Yoshioka R; Fujisawa M; Ogasawara Y; Kitahori M; Yoshioka E; Kubo K; Komeno Y; Kurokawa M; Ogawa S; Chiba S; Osawa T; Kuwaki T; Hirai H; Miwa A
Leuk Res; 2006 Dec; 30(12):1541-6. PubMed ID: 16603240
[TBL] [Abstract][Full Text] [Related]
18. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.
Kim YR; Eom JI; Kim SJ; Jeung HK; Cheong JW; Kim JS; Min YH
J Pharmacol Exp Ther; 2010 Nov; 335(2):389-400. PubMed ID: 20699435
[TBL] [Abstract][Full Text] [Related]
19. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
20. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]